Litigation Details for CELGENE CORPORATION v. APOTEX INC. (D.N.J. 2019)
✉ Email this page to a colleague
CELGENE CORPORATION v. APOTEX INC. (D.N.J. 2019)
| Docket | ⤷ Sign Up | Date Filed | 2019-06-19 |
| Court | District Court, D. New Jersey | Date Terminated | 2021-03-10 |
| Cause | 15:1126 Patent Infringement | Assigned To | Susan Davis Wigenton |
| Jury Demand | None | Referred To | Leda Dunn Wettre |
| Parties | APOTEX INC. | ||
| Patents | 6,315,720; 6,561,977; 6,755,784; 7,189,740; 7,465,800; 7,468,363; 7,855,217; 8,315,886; 8,404,717; 8,626,531; 8,741,929; 9,056,120 | ||
| Attorneys | ROBERT J. SCHOENBERG | ||
| Firms | Saul Ewing Arnstein & Lehr LLP; Steptoe and Johnson LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in CELGENE CORPORATION v. APOTEX INC.
Details for CELGENE CORPORATION v. APOTEX INC. (D.N.J. 2019)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2019-06-19 | 1 | Complaint | alleging that the claims of U.S. Patents No. 6,315,720 (“the ’720 patent”), 6,561,977 (“the …219 patent”), and 8,431,598 (the “’598 patent”), all owned by Celgene (collectively, “the patents-in-…PageID: 7 ’977 patent”), 6,755,784 (“the ’784 patent”), 8,315,886 (“the ’886 patent”), 8,626,531 (“the…“the ’531 patent”), 7,465,800 (“the ’800 patent”), 7,855,217 (“the ’217 patent”), 7,468,363 (“the ’363…claims of U.S. Patents No. 7,189,740 (“the ’740 patent”), 8,404,717 (“the ’717 patent”), and 9,056,120 | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
